Company Analysis
Sign in

Ovid Therapeutics Inc. (OVID)

Nasdaq: OVID · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.8
◀ Past 4.2● Present 5.7▶ Future 6.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$7.3M+1181.3%
Net income-$17.4M+34.1%
Earnings per sharen/a
Operating cash flow-$38.3M+31.5%
Cash$13.2M-50.0%
Debtn/a
Shareholders’ equity$131M+91.5%
Shares, dilutedn/a
Return on equity-13.3%
The recordfrom its filings
Filings in 202658
Newest filingNov 10 · 10-Q
Annual reportMar 18, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted51
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $1.5MNet income -$43.1MCash from operations -$57.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form S-3
Shelf registration
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton OVID · research, not advice